**1. Introduction**

Statins or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors are a worldwide used medication for dyslipidemias, both hypercholesterolemia, and hypertriglyceridemia [1].

These drugs are considered safe and cost-effective, but it is necessary to review the use and possible risk of adverse events. Some frequent adverse drug reactions (ADRs) related to statins affect muscle (myalgia, arthralgia, limb pain, and spasms), liver (elevation of transaminases or creatine kinase), and gastrointestinal system (constipation, flatulence, dyspepsia, nausea, and diarrhea) and are related to infections (nasopharyngitis) [2, 3].

ADRs related to musculoskeletal and connective tissue, such as myopathy, rhabdomyolysis, or myositis, are classified as rare [3]. The withdrawal of cerivastatin in

2001 was due to deaths attributed to drug-related rhabdomyolysis that led to kidney failure [4].

However, besides, there is a group of ADR related to mental status, cataloged as rare or very rare or frequency not known such as insomnia, sleep disorders, depression, cognitive impairment, memory impairment, and nightmares [3, 5]. Some of these events can be confusing and wrongly identified in older patients with mental deterioration [6].

This study aims to make available an early knowledge of signals of statins' adverse reactions related to mental disorders to analyze in future clinical trials and provide a list of candidates for clinical trials.
